The new facility will allow the company to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.
The investment in clinical and commercial scale ADC conjugation is a natural extension to the company’s existing CMO offering and leverages its purification technologies.
Scheduled to be opened in the second quarter of 2016, the new facility will provide contract manufacturing in batch sizes from a few milligrams to 600g to ADC drug developers during clinical trial and commercial development phases.
Novasep Synthesis BU president Thierry Van Nieuwenhove said: "Combining chemistry and biology is not a given. Novasep is one of the few CMOs able to produce both commercial scale ADCs payloads and monoclonal antibodies.
"Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances.
"By integrating our R&D, analytical and manufacturing services within a single unit, we can give customers flexibility, assurance of supply and continuity in supply chains."
Design of the new facility is now complete, and once operational it will be capable of producing ADCs in full compliance with the highest standards in quality, health, environmental and industrial safety, the company said.